A pan tyrosine kinase inhibitor that primarily targets VEGFR2 (IC50 = 0.035 nM) and c-Met (IC50 = 1.3 nM) but also inhibits RET, c-Kit, AXL, FLT3, and Tie2 (IC50 = 5.2, 4.6, 7, 11.3, and 14.3 nM, respectively); reduces tumor and endothelial cell proliferation, targeting both angiogenesis and metastasis in cancers with dysregulated c-Met and VEGFR signaling.